Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Glioma 4Pancreatic Neoplasms 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Gastrointestinal Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Xanthogranuloma, Juvenile 1Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1

Interventions

ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Histiocytic Neoplasms × ulixertinib × Clear all
NCT06411821 2026-05-28

Ulixertinib in People With Histiocytic Neoplasms

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
38 enrolled

Histiocytic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡